Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (GSSF), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress on Friday, September 19. The findings provide comp...

Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support the planned regulatory submissions for povorcitinib in HS in Europe and the United States in 2025 and early 2026, respectively. The presentation will ...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that ADC therapeutics developer, Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen. The antibody will be applied in a novel ADC candidate proprietary to Tubulis. It is part of a previou...

Scientist.com, the leading R&D procurement orchestration platform for the life sciences, today announced a major expansion of its Tumor Model Finder (TMF) following a strategic partnership with XenoSTART, a global leader in patient-derived xenograft (PDX) model development and testing. The addition of hundreds of unique and high-demand XenoSTART models pushes the TMF past a milestone of 10,000 searchable oncology models, giving cancer researchers unprecedented access to diverse and clinical...